Literature DB >> 31089718

Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.

Theophilos Tzaridis1,2, Irina Gepfner-Tuma3,4, Sophie Hirsch3,4, Marco Skardelly3,4, Benjamin Bender4,5, Frank Paulsen4,6, Christina Schaub4, Johannes Weller1, Niklas Schäfer1, Ulrich Herrlinger1, Ghazaleh Tabatabai3,4,7.   

Abstract

Entities:  

Keywords:  hand foot reaction; high-grade glioma; regorafenib

Year:  2019        PMID： 31089718      PMCID： PMC6620634          DOI： 10.1093/neuonc/noz071

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Authors:  Walter Taal; Hendrika M Oosterkamp; Annemiek M E Walenkamp; Hendrikus J Dubbink; Laurens V Beerepoot; Monique C J Hanse; Jan Buter; Aafke H Honkoop; Dolf Boerman; Filip Y F de Vos; Winand N M Dinjens; Roelien H Enting; Martin J B Taphoorn; Franchette W P J van den Berkmortel; Rob L H Jansen; Dieta Brandsma; Jacoline E C Bromberg; Irene van Heuvel; René M Vernhout; Bronno van der Holt; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

2.  Lomustine and Bevacizumab in Progressive Glioblastoma.

Authors:  Wolfgang Wick; Thierry Gorlia; Martin Bendszus; Martin Taphoorn; Felix Sahm; Inga Harting; Alba A Brandes; Walter Taal; Julien Domont; Ahmed Idbaih; Mario Campone; Paul M Clement; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Andreas von Deimling; Vassilis Golfinopoulos; Jacoline C Bromberg; Michael Platten; Martin Klein; Martin J van den Bent
Journal:  N Engl J Med       Date:  2017-11-16       Impact factor: 91.245

Review 3.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Authors:  Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick
Journal:  Lancet Oncol       Date:  2017-05-05       Impact factor: 41.316

4.  Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Authors:  Christina Schaub; Julia Tichy; Niklas Schäfer; Kea Franz; Frederic Mack; Michel Mittelbronn; Sied Kebir; Anna-Luisa Thiepold; Andreas Waha; Natalie Filmann; Mohammed Banat; Rolf Fimmers; Joachim P Steinbach; Ulrich Herrlinger; Johannes Rieger; Martin Glas; Oliver Bähr
Journal:  J Neurooncol       Date:  2016-05-18       Impact factor: 4.130

5.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

6.  Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

Authors:  Giuseppe Lombardi; Gian Luca De Salvo; Alba Ariela Brandes; Marica Eoli; Roberta Rudà; Marina Faedi; Ivan Lolli; Andrea Pace; Bruno Daniele; Francesco Pasqualetti; Simona Rizzato; Luisa Bellu; Ardi Pambuku; Miriam Farina; Giovanna Magni; Stefano Indraccolo; Marina Paola Gardiman; Riccardo Soffietti; Vittorina Zagonel
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316
  6 in total
  5 in total

1.  Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review.

Authors:  Mario Pirozzi; Marianna Caterino; Sergio Facchini; Alessia Zotta; Gaetana Messina; Raffaele Rauso; Antonello Sica; Donato Sciano; Gaetano Facchini; Michele Orditura; Teresa Somma; Francesco Maiuri; Paolo Cappabianca; Fortunato Ciardiello; Morena Fasano
Journal:  Case Rep Oncol       Date:  2022-06-27

2.  Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Authors:  Pia S Zeiner; Martina Kinzig; Iris Divé; Gabriele D Maurer; Katharina Filipski; Patrick N Harter; Christian Senft; Oliver Bähr; Elke Hattingen; Joachim P Steinbach; Fritz Sörgel; Martin Voss; Eike Steidl; Michael W Ronellenfitsch
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

3.  Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.

Authors:  Jan-Michael Werner; Lena Wolf; Caroline Tscherpel; Elena K Bauer; Michael Wollring; Garry Ceccon; Martina Deckert; Anna Brunn; Roberto Pappesch; Roland Goldbrunner; Gereon R Fink; Norbert Galldiks
Journal:  J Neurooncol       Date:  2022-06-18       Impact factor: 4.506

4.  Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.

Authors:  Hannes Treiber; Christian von der Brelie; Vesna Malinova; Dorothee Mielke; Veit Rohde; Claudia Ilse Chapuy
Journal:  Neurosurg Rev       Date:  2022-06-20       Impact factor: 2.800

5.  Regorafenib in glioblastoma recurrence: how to deal with conflicting 'real-life' experiences?

Authors:  Martin Glas; Sied Kebir
Journal:  Ther Adv Med Oncol       Date:  2019-12-16       Impact factor: 8.168
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.